Your browser is no longer supported. Please, upgrade your browser.
Gain Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.60 Insider Own1.80% Shs Outstand11.88M Perf Week-2.23%
Market Cap82.69M Forward P/E- EPS next Y-2.04 Insider Trans0.00% Shs Float8.26M Perf Month-6.52%
Income-7.10M PEG- EPS next Q-0.34 Inst Own11.70% Short Float0.30% Perf Quarter-16.85%
Sales0.10M P/S826.95 EPS this Y-63.10% Inst Trans-6.88% Short Ratio0.19 Perf Half Y-38.68%
Book/sh3.48 P/B2.14 EPS next Y-38.80% ROA- Target Price- Perf Year-
Cash/sh3.89 P/C1.91 EPS next 5Y- ROE- 52W Range6.90 - 17.93 Perf YTD-33.48%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-58.00% Beta-
Dividend %- Quick Ratio18.10 Sales past 5Y- Gross Margin- 52W Low9.13% ATR0.61
Employees16 Current Ratio18.10 Sales Q/Q- Oper. Margin- RSI (14)45.04 Volatility6.96% 6.55%
OptionableNo Debt/Eq0.02 EPS Q/Q- Profit Margin- Rel Volume0.10 Prev Close7.45
ShortableYes LT Debt/Eq0.01 Earnings- Payout- Avg Volume135.35K Price7.53
Recom1.00 SMA20-5.93% SMA50-8.60% SMA200-26.03% Volume2,129 Change1.08%
Apr-12-21Initiated Oppenheimer Outperform $30
Apr-12-21Initiated BTIG Research Buy $30
Sep-17-21 08:00AM  
Sep-09-21 04:20PM  
Sep-08-21 03:51PM  
Sep-02-21 04:05PM  
Aug-11-21 04:01PM  
Aug-03-21 04:05PM  
Jun-21-21 05:49PM  
Jun-19-21 05:49AM  
Jun-10-21 07:30AM  
May-27-21 08:00AM  
May-17-21 08:00AM  
May-10-21 04:01PM  
May-03-21 07:30AM  
Apr-27-21 04:01PM  
Apr-22-21 08:00AM  
Apr-20-21 08:00AM  
Apr-14-21 09:13PM  
Mar-25-21 05:57PM  
Mar-18-21 05:08PM  
Gain Therapeutics, Inc., a development stage biotechnology company, engages in developing various therapeutics to treat diseases caused by protein misfolding. It focuses rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover novel allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites and restore protein folding, treating the underlying disease. It is developing structurally targeted allosteric regulator candidates in various preclinical studies to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RICHMAN ERIC IDirectorAug 16Option Exercise7.874,92238,716216,820Aug 17 09:03 PM